A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Active:	Yes
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT06926868
Trial Phases:	Phase II Phase III	Protocol IDs:	CA244-0008 (primary) NCI-2025-03934 2024-519871-24 U1111-1316-1533
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT06926868

Summary

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific
antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload
versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin
plus gemcitabine, and capecitabine) for the treatment of first-line metastatic
triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal
growth factor receptor 2 (HER2)-negative BC patients who are not candidates for
anti-PD(L)1 therapy and endocrine therapies.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Doctors:

Amelia B. Zelnak MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.